Prospective, non-interventional study of ruxolitinib therapy in patients with polycythaemia vera – German real-world data (PaVe study)
Annals of Hematology · 12.05.2026 · 105 (6)
DOI: 10.1007/s00277-026-06947-9 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Annals of Hematology, online erschienen am 12.05.2026. Verfasst von Martin Griesshammer und 9 weiteren Autor:innen. Beteiligte Einrichtung: University Clinic for Hematology and Oncology, Johannes Wesling Clinic Minden, University Bochum, Minden, Germany. Martin.Griesshammer@muehlenkreiskl…. Hauptthemen laut MEDLINE: Pyrazoles, Polycythemia Vera. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Knappschaftskrankenhaus Bochum GmbH.
Abstract (Originalsprache)
Ruxolitinib, a JAK1/JAK2 inhibitor, has demonstrated efficacy in achieving hematocrit control, spleen volume reductions, and symptom improvement in patients with polycythaemia vera (PV) resistant to or intolerant of hydroxyurea in clinical trials. PaVe is a prospective, noninterventional study of patients with PV who received ruxolitinib in a real-world setting in Germany. Observational parameters included effectiveness, safety, patient satisfaction and quality of life. Patients with and without prior treatment with ruxolitinib were included in this study. Additionally, patients were stratified by no/high risk. The study was primarily analyzed using descriptive methods. Four hundred and thirty-three patients with PV were included in this study, of which 62% were pretreated with a JAK-inhibitor and 38% were not. Mean decreases from Baseline in hematocrit levels/leukocyte counts at the last assessment were more pronounced in naïve patients (-6.2% versus − 1.6%/-4.5 × 10 3 /µl versus − 1.4 × 10 3 /µl) and high-risk patients (-6.3% versus − 5.3%/-4.8 × 10 3 /µl versus − 2.6 × 10 3 /µl). Mean decreases from Baseline in thrombocyte counts at the last assessment were more pronounced in naïve patients (-80.5 × 10 3 /µl versus − 42.6 × 10 3 /µl) and no-risk patients (-108.0 × 10 3 /µl versus − 77.1 × 10 3 /µl). There was almost no difference in the total number of thromboembolic events in JAK inhibitor naïve versus JAK inhibitor pretreated patients (3.1%, n = 5 versus 3.8%, n = 10). No new safety concerns were observed with ruxolitinib. Findings from this study in a real-world setting show that ruxolitinib is an effective and safe second-line treatment in PV patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University Clinic for Hematology and Oncology, Johannes Wesling Clinic Minden, University Bochum, Minden, Germany. Martin.Griesshammer@muehlenkreiskliniken.de.
- Oncology at Raschplatz, Hannover, Germany.
- Hematology-Oncology Specialist Practice, Würzburg, Germany.
- Hematology and Oncology München-Pasing MVZ GmbH, München, Germany.
- Collective Practice, Erfurt, Germany.
- Oncology Outpatient Center, Hannover, Germany.
Förderung
- Universitätsklinikum Knappschaftskrankenhaus Bochum GmbH
Zitieren
APA
Griesshammer, M., von der Heyde, E., Schlag, R., Schmidt, B., Weniger, S., Koenigsmann, M., Stauch, M., Gückel, E., Baum, V., & Weide, R. (2026). Prospective, non-interventional study of ruxolitinib therapy in patients with polycythaemia vera – German real-world data (PaVe study). Annals of Hematology, 105(6). https://doi.org/10.1007/s00277-026-06947-9
Vancouver
Griesshammer M, von der Heyde E, Schlag R, Schmidt B, Weniger S, Koenigsmann M, et al. Prospective, non-interventional study of ruxolitinib therapy in patients with polycythaemia vera – German real-world data (PaVe study). Annals of Hematology. 2026;105(6). doi:10.1007/s00277-026-06947-9
BibTeX
@article{Griesshammer2026,
author = {Griesshammer, Martin and von der Heyde, Eyck and Schlag, Rudolf and Schmidt, Burkhard and Weniger, Steffi and Koenigsmann, Michael and Stauch, Martina and Gückel, Eva and Baum, Volker and Weide, Rudolf},
title = {Prospective, non-interventional study of ruxolitinib therapy in patients with polycythaemia vera – German real-world data (PaVe study)},
journal = {Annals of Hematology},
year = {2026},
volume = {105},
number = {6},
doi = {10.1007/s00277-026-06947-9}
}
EUVIMED